medicare and glp-1 Weight-Loss Drug Demonstration Begins July 2026 Medicare GLP-1 Bridge Explained: What

DiMarchi, who was a vice president at Eli Lilly and involved in GLP-1 research there, until he left the company in 2003, is that many diseases may share the same root causes, even though we label them and treat them as distinct: This is an endocrine disease, this is a cardiovascular disease, this is a brain disease. This root-cause theory suggests that a wide range of conditions can be treatable with one drug class, sometimes through pathways in the brain and the immune system

GLP-1 is a peptide hormone generated from proglucagon that is secreted after meals by enteroendocrine L-cells in the distal jejunum, ileum, and colon

doi: 10.1016/S2213-8587(20)30075-9

We are very pleased that Wegovy is now approved in the U.S